A Phase II Trial of Nonmyeloablative Haploidentical Peripheral Blood Stem Cell Transplantation Followed By Maintenance Therapy With the Novel Oral Proteasome Inhibitor, MLN9708, in Patients With High-risk Hematologic Malignancies
Phase of Trial: Phase II
Latest Information Update: 13 Jun 2017
At a glance
- Drugs Ixazomib (Primary)
- Indications Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Chronic myeloid leukaemia; Hodgkin's disease; Multiple myeloma; Myelodysplastic syndromes; Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- 29 Feb 2016 Planned End Date changed from 1 Jun 2019 to 1 Jun 2020, according to ClinicalTrials.gov record.
- 29 Feb 2016 Planned primary completion date changed from 1 Jul 2016 to 1 Dec 2017, according to ClinicalTrials.gov record.
- 07 Oct 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.